Paper Details

  1. Home
  2. Paper Details

Dronedarone in high-risk permanent atrial fibrillation.

Author: , AfzalRizwan, AlingsMarco, AmerenaJohn, AtarDan, AvezumÁlvaro, Baret-CormelLydie, BlomströmPer, BorggrefeMartin, BudajAndrzej, CammA John, ChenShih-Ann, ChingChi Keong, ChrolaviciusSusan, CommerfordPatrick, ConnollyStuart J, DansAntonio, DavyJean-Marc, DelacrétazEtienne, Di PasqualeGiuseppe, DiazRafael, DorianPaul, FlakerGreg, GolitsynSergey, Gonzalez-HermosilloAntonio, GrangerChristopher B, HalperinJonathan L, HeidbüchelHein, HohnloserStefan H, JoynerCampbell, KautznerJosef, KimJune Soo, LanasFernando, LewisBasil S, MerinoJose L, MorilloCarlos, MurinJan, NarasimhanCalambur, PaolassoErnesto, ParkhomenkoAlexander, PetersNicholas S, SimKui-Hian, StaigerChristoph, StilesMartin K, TanomsupSupachai, ToivonenLauri, TomcsányiJános, Torp-PedersenChristian, TseHung-Fat, VardasPanos, VinereanuDragos, WeinlingEstelle, XavierDenis, YusufSalim, ZhuJun, ZhuJun-Ren

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study hypothesized that dronedarone would reduce major vascular events in high-risk permanent atrial fibrillation.
Paper Details　
Original Abstract of the Article :
Dronedarone restores sinus rhythm and reduces hospitalization or death in intermittent atrial fibrillation. It also lowers heart rate and blood pressure and has antiadrenergic and potential ventricular antiarrhythmic effects. We hypothesized that dronedarone would reduce major vascular events in hig...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa1109867

データ提供：米国国立医学図書館（NLM）

Dronedarone: A Potential Treatment Option for High-Risk Permanent Atrial Fibrillation

This research focuses on the potential benefits of dronedarone, a medication used to manage atrial fibrillation (AFib). The study explores the possibility of using dronedarone to reduce major vascular events in patients with high-risk permanent AFib. The authors examine the effects of dronedarone on heart rate, blood pressure, and its potential antiarrhythmic properties.

Dronedarone's Potential for Reducing Vascular Events

The study hypothesized that dronedarone could play a significant role in reducing major vascular events in high-risk permanent AFib patients. While the study's findings are promising, further research is needed to definitively confirm its efficacy in this patient population. The authors suggest that dronedarone's ability to restore sinus rhythm, lower heart rate, and reduce blood pressure could contribute to its potential for reducing vascular events in this high-risk group.

Implications for Managing Atrial Fibrillation

The findings of this study suggest that dronedarone could be a valuable addition to the treatment arsenal for high-risk permanent AFib. Further research is needed to determine its optimal role in managing this complex condition. Understanding the potential benefits and risks of dronedarone in this patient population is crucial for making informed clinical decisions. It's like navigating the complex landscape of AFib treatment, seeking the most effective strategies to manage this challenging condition.

Dr. Camel's Conclusion

This study explores the potential of dronedarone as a treatment option for high-risk permanent AFib. The findings suggest that dronedarone may offer benefits in reducing vascular events, but further research is needed to confirm its efficacy. It's like seeking a path through the vast desert of AFib treatment options, hoping to find a route that leads to improved patient outcomes.

Date :
  1. Date Completed 2011-12-22
  2. Date Revised 2023-08-15
Further Info :

Pubmed ID

22082198

DOI: Digital Object Identifier

10.1056/NEJMoa1109867

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.